PMID- 32620205
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20200716
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 107
IP  - 5S
DP  - 2020 Jun
TI  - [Oligorecurrent prostate cancer: current management and perspectives].
PG  - S35-S40
LID - S0007-4551(20)30276-9 [pii]
LID - 10.1016/S0007-4551(20)30276-9 [doi]
AB  - Oligometastatic prostate cancer (PCa) is an intense area of research thanks to 
      the development of novel PET tracers such as (18)F-choline or (68)Ga-PSMA. 
      Several retrospective studies in patients with hormone-sensitive oligorecurrent 
      PCa (usually up to 5 metastases with a controlled primary tumor) showed PSA 
      response and a low toxicity profile of metastasis-directed therapies (MDT) such 
      as Stereotactic Body Radiation Therapy (SBRT) or salvage lymph node dissection. 
      More recently, randomized phase 2 studies showed that SBRT can delay the 
      introduction of androgen deprivation, decrease biochemical relapses and increase 
      overall survival. Regarding oligoprogressive metastatic castration-resistant PCa, 
      limited data is however available. Based on these studies the European 
      Association of Urology and the American Society of Radiotherapy EAU now recommend 
      using MDT instead of observation. Several studies are undergoing in France and 
      worldwide in order to confirm the exact role of MDT.
CI  - Copyright (c) 2020 Societe Francaise du Cancer. Publie par Elsevier Masson SAS. 
      Tous droits reserves.
FAU - Loubersac, Thomas
AU  - Loubersac T
AD  - Urologie, Hotel-Dieu, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes, 
      France.
FAU - Guimas, Valentine
AU  - Guimas V
AD  - Service de radiotherapie, Institut de cancerologie de l'Ouest, boulevard 
      Professeur-Jacques-Monod, 44800 Nantes Saint-Herblain, France.
FAU - Rio, Emmanuel
AU  - Rio E
AD  - Service de radiotherapie, Institut de cancerologie de l'Ouest, boulevard 
      Professeur-Jacques-Monod, 44800 Nantes Saint-Herblain, France.
FAU - Libois, Vincent
AU  - Libois V
AD  - Service de radiotherapie, Institut de cancerologie de l'Ouest, boulevard 
      Professeur-Jacques-Monod, 44800 Nantes Saint-Herblain, France.
FAU - Rigaud, Jerome
AU  - Rigaud J
AD  - Urologie, Hotel-Dieu, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes, 
      France.
FAU - Supiot, Stephane
AU  - Supiot S
AD  - Service de radiotherapie, Institut de cancerologie de l'Ouest, boulevard 
      Professeur-Jacques-Monod, 44800 Nantes Saint-Herblain, France. Electronic 
      address: stephane.supiot@ico.unicancer.fr.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Prise en charge des rechutes oligometastatiques des cancers de prostate : 
      actualites et perspectives.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
SB  - IM
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local/*therapy
MH  - Prostatic Neoplasms/*therapy
OTO - NOTNLM
OT  - Cancer de prostate
OT  - Choline PET
OT  - Oligometastatic
OT  - Oligoprogression
OT  - Oligoprogressive
OT  - Oligorecurrent
OT  - Oligorecurrence
OT  - PSMA
OT  - Radiotherapie
OT  - SBRT
OT  - TEP-FCH
OT  - oligometastatique
OT  - prostate cancer
OT  - stereotaxique
EDAT- 2020/07/06 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/07/05 06:00 [entrez]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - S0007-4551(20)30276-9 [pii]
AID - 10.1016/S0007-4551(20)30276-9 [doi]
PST - ppublish
SO  - Bull Cancer. 2020 Jun;107(5S):S35-S40. doi: 10.1016/S0007-4551(20)30276-9.